A new kid in the folding funnel: Molecular chaperone activities of the BRICHOS domain
Axel Leppert1,2, Helen Poska3, Michael Landreh2
1Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.
Insights
The BRICHOS protein superfamily, implicated in diseases like dementia and cancer, features a domain that chaperones proteins during biosynthesis. This review explores their diverse molecular chaperone functions and therapeutic potential for protein aggregation disorders.
Area of Science:
- Biochemistry
- Molecular Biology
- Protein Folding
Background:
- The BRICHOS protein superfamily is linked to various human diseases, including respiratory distress, COVID-19, dementia, and cancer.
- These proteins possess a BRICHOS domain and an aggregation-prone region, with the domain proposed to chaperone substrates during biosynthesis.
- BRICHOS domains modulate amyloid-forming substrate aggregation pathways, with varying capacities to maintain protein folding competence.
Purpose of the Study:
- To provide an overview of the BRICHOS protein family.
- To explore the diverse molecular chaperone-like functions of BRICHOS domains in relation to their structure and conformational plasticity.
- To discuss the physiological implications of these chaperone functions and their potential therapeutic use.
Main Methods:
- Literature review and analysis of existing evidence on BRICHOS proteins.
- Examination of structure-function relationships of BRICHOS domains.
- Exploration of potential therapeutic applications based on molecular chaperone activity.
Main Results:
- BRICHOS domains exhibit diverse molecular chaperone activities, influencing aggregation pathways of various substrates.
- The quaternary structure and surface motifs of BRICHOS domains dictate their ability to interfere with substrate aggregation.
- The conformational plasticity of BRICHOS domains is crucial for their chaperone function.
Conclusions:
- BRICHOS domains possess versatile molecular chaperone functions critical for protein homeostasis.
- Their structure and plasticity determine their efficacy in modulating protein aggregation.
- BRICHOS domains hold promise as potential therapeutic agents for protein aggregation disorders, including potential blood-brain barrier permeability.
Abstract:
The BRICHOS protein superfamily is a diverse group of proteins associated with a wide variety of human diseases, including respiratory distress, COVID-19, dementia, and cancer. A key characteristic of these proteins-besides their BRICHOS domain present in the ER lumen/extracellular part-is that they harbor an aggregation-prone region, which the BRICHOS domain is proposed to chaperone during biosynthesis. All so far studied BRICHOS domains modulate the aggregation pathway of various amyloid-forming substrates, but not all of them can keep denaturing proteins in a folding-competent state, in a similar manner as small heat shock proteins. Current evidence suggests that the ability to interfere with the aggregation pathways of substrates with entirely different end-point structures is dictated by BRICHOS quaternary structure as well as specific surface motifs. This review aims to provide an overview of the BRICHOS protein family and a perspective of the diverse molecular chaperone-like functions of various BRICHOS domains in relation to their structure and conformational plasticity. Furthermore, we speculate about the physiological implication of the diverse molecular chaperone functions and discuss the possibility to use the BRICHOS domain as a blood-brain barrier permeable molecular chaperone treatment of protein aggregation disorders.
More Related Videos
Related Concept Videos
Molecular Chaperones and Protein Folding
The...
Bacterial Protein Maturation
Protein Folding
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
Regulation of the Unfolded Protein Response
Protein Folding Quality Check in the RER
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...


